LEEM negotiates new sales rep working time rules

13 July 2008

France's drug industry association (LEEM) is attempting to negotiate a deal with labor unions over the way that marketing visits by drug company representatives are recorded. The group argues that there is a need to change the existing arrangements which date from 1956 and are based on an equivalence between working time and the number of physician visits.

In a statement, the LEEM argued that the current arrangements are no longer adequate for the diversity and spread of geographic sectors, the complexity of new products and the number of stakeholders who need to be kept informed of a firm's innovative drugs. The drugmakers' representative group proposed a reduction in the 218-day limit on days worked per year using a new accounting method for recording sales visits. However, talks between the LEEM and the unions appear to be stalling with two of them, the CFDT and the SNPADVM, accepting the principle of a pay scale based on 203 days.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight